What are the mechanism of action, elimination half‑life, interactions with P‑glycoprotein and CYP2D6, effects on QT interval, and effects on cardiac conduction of mitragynine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mitragynine: Pharmacological Profile and Cardiac Effects

Mitragynine acts primarily as an antagonist at α2-adrenergic receptors and serotonin receptors (5-HT2, 5-HT3), with significant cardiac risks including hERG channel blockade, QT prolongation, and potential for Torsade de Pointes, particularly at higher doses.

Mechanism of Action

Mitragynine's therapeutic effects are mediated through multiple receptor interactions 1, 2:

  • α2-adrenergic receptor antagonism at presynaptic inhibitory autoreceptors and heteroreceptors, enhancing noradrenergic activity
  • Serotonin receptor antagonism at 5-HT2 and 5-HT3 receptors
  • Histamine H1 receptor antagonism (contributing to sedation)
  • Peripheral α1-adrenergic receptor antagonism (contributing to orthostatic hypotension)
  • Opioid-like effects through mechanisms not fully elucidated

Elimination Half-Life

The elimination half-life of mitragynine ranges from 20 to 40 hours following oral administration 3. Important pharmacokinetic considerations include:

  • Steady-state plasma levels achieved within 5 days
  • Accumulation ratio of approximately 1.5
  • The (–) enantiomer has an elimination half-life approximately twice as long as the (+) enanomer, achieving plasma levels about 3 times higher
  • Gender differences: Females exhibit significantly longer elimination half-lives (mean 37 hours) compared to males (mean 26 hours) 3

P-glycoprotein Interactions

Mitragynine acts as a P-glycoprotein (P-gp) inhibitor 4. This has critical clinical implications:

  • Mitragynine inhibits P-gp transport activity by binding to the nucleotide-binding domain site
  • Forms a stable interaction with the P-gp protein complex
  • At nontoxic concentrations (<4 μM), mitragynine significantly enhances endothelial cell permeability at the blood-brain barrier
  • Concurrent administration with P-gp substrates may lead to clinically significant drug interactions and neurotoxicity 4

This P-gp inhibition is particularly concerning when mitragynine is combined with other P-gp substrate medications, as it may increase their CNS penetration and toxicity risk.

CYP2D6 and Other Metabolic Interactions

Mitragynine is predominantly metabolized by CYP3A4, with minor contributions from CYP2D6 and CYP2C9 5. The metabolic profile includes:

Primary Metabolism

  • CYP3A4 is the predominant enzyme responsible for mitragynine clearance
  • CYP3A4 catalyzes formation of five oxidative metabolites and converts mitragynine to 7-hydroxymitragynine (an active metabolite with known potency)
  • CYP2D6 and CYP2C9 play minor roles in metabolism 5

Drug Interaction Implications

Based on the FDA label data for similar compounds 3:

  • Strong CYP3A4 inhibitors (e.g., ketoconazole) can increase mitragynine exposure by approximately 40-50%
  • CYP3A4 inducers (e.g., carbamazepine, phenytoin) can increase clearance by approximately 2-fold, decreasing plasma concentrations by 45-60%
  • CYP2D6 inhibitors may have modest effects on mitragynine metabolism given its minor role

Clinical Monitoring

  • Patients on strong CYP3A4 inhibitors or inducers require careful monitoring for altered mitragynine effects
  • Dose adjustments may be necessary when combining with CYP3A4 modulators

Effects on QT Interval

Mitragynine causes dose-dependent QT prolongation and carries significant risk for Torsade de Pointes 1, 2, 6:

Mechanism of QT Prolongation

  • hERG channel blockade with IC50 values of 1.15-1.62 μM in experimental models 1
  • Mitragynine interacts with high-affinity drug-binding sites (Y652A and F656A) in the hERG channel pore cavity 1
  • Inhibits the cardiac IKr current, which is a critical determinant of ventricular action potential duration and QT interval

Clinical Cardiac Effects

In human-induced pluripotent stem cell-derived cardiomyocytes 2:

  • At 10 μM, mitragynine suppressed IKr by 67-84%
  • Significantly prolonged action potential duration at 50% repolarization (APD50): 439.0 ms → 585.2 ms
  • Significantly prolonged action potential duration at 90% repolarization (APD90): 536.0 ms → 705.9 ms
  • Induced arrhythmias in experimental models

Additional Cardiac Risks

Mitragynine also inhibits IKACh current (IC50 = 3.32 μM) mediated by GIRK channels 1. Blocking both hERG and GIRK channels creates additive cardiotoxicity risks, potentially explaining the cardiac arrests reported in fatal cases.

Effects on Cardiac Conduction

Mitragynine has multiple adverse effects on cardiac conduction and rhythm 2, 6:

Documented Cardiovascular Effects

  • Tachycardia (most common adverse effect)
  • Hypertension (most common adverse effect)
  • Ventricular arrhythmias including Torsade de Pointes risk
  • Dose-dependent QTc prolongation
  • Cardiomyopathy in some cases
  • Myocarditis
  • Cardiopulmonary arrest in severe cases

Conduction System Impact

Unlike tricyclic antidepressants that delay AV-node conduction 7, mitragynine's primary conduction effects appear to be:

  • Ventricular repolarization abnormalities (QT prolongation)
  • Arrhythmia induction through hERG and GIRK channel blockade
  • No significant effect on L-type Ca2+ current 2

Clinical Caveats and Risk Mitigation

High-Risk Scenarios

Avoid mitragynine or use extreme caution in patients with:

  • Pre-existing QT prolongation or congenital long QT syndrome
  • Concurrent use of other QT-prolonging medications 7, 3
  • Electrolyte abnormalities (hypokalemia, hypomagnesemia)
  • Structural heart disease or cardiomyopathy
  • Concurrent use of CYP3A4 inhibitors (increases mitragynine exposure)
  • Concurrent use of P-gp substrates (risk of neurotoxicity)

Monitoring Recommendations

For patients using mitragynine:

  • Baseline ECG to assess QTc interval
  • Electrolyte monitoring (potassium, magnesium)
  • Medication review for QT-prolonging drugs and CYP3A4/P-gp interactions
  • Cardiovascular symptom surveillance (palpitations, syncope, chest pain)

Drug Interaction Management

Following the algorithmic approach from anticoagulant DDI management 8:

  • Screen for CYP3A4 modulators and P-gp substrates
  • Assess additive risks when combining with other cardiotoxic agents
  • Consider dose reduction when strong CYP3A4 inhibitors are necessary
  • Increase monitoring frequency when drug interactions are unavoidable

The combination of hERG blockade, GIRK channel inhibition, P-gp inhibition, and extensive CYP3A4 metabolism creates a complex pharmacological profile with significant potential for both pharmacokinetic and pharmacodynamic drug interactions, particularly affecting cardiac safety 1, 4, 2, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.